Safety and efficacy of mycophenolate in COVID-19
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
The Lancet regional health. Southeast Asia - 22(2024) vom: 23. März, Seite 100321 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zeng, Guangting [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 15.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.lansea.2023.100321 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36971850X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM36971850X | ||
003 | DE-627 | ||
005 | 20240315234243.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.lansea.2023.100321 |2 doi | |
028 | 5 | 2 | |a pubmed24n1330.xml |
035 | |a (DE-627)NLM36971850X | ||
035 | |a (NLM)38482156 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zeng, Guangting |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety and efficacy of mycophenolate in COVID-19 |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 15.03.2024 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Liu, Xiangting |e verfasserin |4 aut | |
700 | 1 | |a Wang, Xia |e verfasserin |4 aut | |
700 | 1 | |a Li, Hui |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Southeast Asia |d 2022 |g 22(2024) vom: 23. März, Seite 100321 |w (DE-627)NLM342899503 |x 2772-3682 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2024 |g day:23 |g month:03 |g pages:100321 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lansea.2023.100321 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2024 |b 23 |c 03 |h 100321 |